The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
- PMID: 33893398
- PMCID: PMC8063779
- DOI: 10.1038/s41422-021-00496-8
The basis of a more contagious 501Y.V1 variant of SARS-CoV-2
Conflict of interest statement
H.L. is partially supported by NB Life Laboratory LLC and G.Z. holds equity at NB Life Laboratory LLC.
Figures

Update of
-
The basis of a more contagious 501Y.V1 variant of SARS-COV-2.bioRxiv [Preprint]. 2021 Feb 2:2021.02.02.428884. doi: 10.1101/2021.02.02.428884. bioRxiv. 2021. Update in: Cell Res. 2021 Jun;31(6):720-722. doi: 10.1038/s41422-021-00496-8. PMID: 33564771 Free PMC article. Updated. Preprint.
References
-
- U. S. Food & Drug. Pfizer-BioNTech vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).
-
- U. S. Food & Drug. Moderna vaccine. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-dise... (2020).
-
- CDC. SARS-CoV-2 variants. https://www.cdc.gov/coronavirus/2019-ncov/more/science-and-research/scie... (2021).
-
- U. S. Food & Drug. Bamlanivimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).
-
- U. S. Food & Drug. Casirivimab & imdevimab. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... (2020).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous